Bimuno® GOS and reducing gastro-intestinal discomfort


Bimuno®, GOS, β-galacto-oligosaccharides, gastro-intestinal discomfort, health claims
First published in the EFSA Journal
14 July 2014
25 June 2014
Scientific Opinion

Following an application from Clasado Limited, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Malta, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Bimuno® GOS and reducing gastro-intestinal discomfort. The food constituent that is the subject of the health claim, Bimuno® GOS, which is a mixture of β‑galacto-oligosaccharides produced through conversion of lactose by enzymes from Bifidobacterium bifidum NCIMB 41171, is sufficiently characterised. The claimed effect is reducing gastro-intestinal discomfort and is considered to be a beneficial physiological effect. The applicant did not provide any studies from which data could be used for the scientific substantiation of the claimed effect of reducing gastro-intestinal discomfort. A cause and effect relationship has not been established between the consumption of Bimuno® GOS and reducing gastro-intestinal discomfort.

Panel members at the time of adoption
Carlo Agostoni, Roberto Berni Canani, Susan Fairweather-Tait, Marina Heinonen, Hannu Korhonen, Sébastien La Vieille, Rosangela Marchelli, Ambroise Martin, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna Nowicka, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Sean (J.J.) Strain, Inge Tetens, Daniel Tomé, Dominique Turck and Hans Verhagen.
Panel on Dietetic Products, Nutrition and Allergies
nda [at]
EFSA Journal 2014;12(7):3756 [13 pp.].
Question Number
On request from
Competent Authority of Malta following an application by Clasado Limited
Print on demand
Number of Pages